



A-JMRHS

THE MICROECOLOGICAL AETIOLOGY OF ORAL CANCER: DECIPHERING THE ROLE OF THE ORAL MICROBIOME IN THE MALIGNANT TRANSFORMATION OF OPMDS

Dr. Jayesh Kanjariya¹, Dr. Jinal Koladiya², Dr. Ruchi Patel³, Dr. Jigar Thakkar⁴, Dr. Kruti Patel⁵, Dr. Kavita Prajapati⁶, Dr. Keval Patel^{7*}

¹Reader, Department of Oral Pathology, Ahmedabad Dental College, Ahmedabad, Gujarat, India.

^{2,3,4,5,6}PG Student, Department of Oral Pathology, Ahmedabad Dental College, Ahmedabad, Gujarat, India.

⁷MDS in Orthodontics, Private Clinic.

Corresponding Author: Dr. Keval Patel

MDS in Orthodontics, Private Clinic.

Email: Keval.R.Patel@Gmail.Com

ABSTRACT

The malignant transformation of oral potentially malignant disorders (OPMDs) into oral squamous cell carcinoma (OSCC) has traditionally been viewed through the narrow lens of host genomic instability and cumulative environmental mutagenesis. However, the diagnostic paradigm is currently undergoing a profound shift. Advanced multi-omics sequencing has unveiled a vast, highly active oral microecosystem that does not merely colonise neoplastic tissue opportunistically, but actively orchestrates the aetiopathogenesis of the tumour. This review exhaustively examines the transition from microbial haemostasis to pathogenic dysbiosis within OPMDs. By mapping the specific mechanisms through which keystone periopathogens—namely *Fusobacterium nucleatum* and *Porphyromonas gingivalis*—induce the epithelial-mesenchymal transition (EMT), hyperactivate inflammatory signalling cascades, and subvert local immune surveillance, this manuscript provides a comprehensive molecular framework. Integrating microbial landscaping into routine oral pathology offers profound new avenues for predicting malignant transformation and designing targeted microecological therapies.

The Shifting Paradigm in Oral Pathology

Oral squamous cell carcinoma represents the terminal, invasive stage of a complex, multi-step oncogenic process that frequently originates from distinct, clinically visible precursor lesions. These lesions, collectively categorised as oral potentially malignant disorders (OPMDs), include homogeneous leucoplakia, erythroplakia, oral submucous fibrosis, and the exceptionally aggressive proliferative verrucous leukoplakia (PVL)¹. For decades, the cornerstone of risk stratification in oral pathology has relied upon the histopathological grading of epithelial dysplasia—a process inherently limited by subjective morphological interpretation and spatial sampling errors².

While genomic aberrations in key regulatory genes such as *TP53* and *NOTCH1* are undisputed drivers of cellular immortalisation, host genetics alone cannot fully account for the erratic and unpredictable clinical trajectories observed in OPMDs. In recent years, high-throughput 16S rRNA gene sequencing and shotgun metagenomics have illuminated a pivotal "third driver" of oncogenesis: the local oral microbiome³.

It is now scientifically established that the transition from a clinically healthy mucosal architecture to dysplasia, and ultimately to a frankly invasive carcinoma, is intrinsically linked to profound microbial dysbiosis. The microbiome acts as an active, metabolic organ, continuously interacting with the host's epithelial and immune cells to either maintain structural haemostasis or drive protumorigenic inflammation⁴.

From Symbiotic Haemostasis to Oncogenic Dysbiosis

The human oral cavity is a highly dynamic ecological niche, harbouring the second most diverse microbiota in the body, encompassing over 700 distinct bacterial species alongside a complex array of fungi and viruses. In a state of physiological health, this microenvironment exists in a delicate, symbiotic balance. The predominant healthy phyla—primarily *Firmicutes* and *Bacteroidota* (including non-pathogenic *Streptococcus* species)—form a protective biofilm that competitively



www.ajmrhs.com
eISSN: 2583-7761

Date of Received: 26-04-2026
Date Acceptance: 05-05-2026
Date of Publication: 06-06-2026

excludes highly virulent pathogens and maintains the integrity of the epithelial basement membrane⁵. The onset of an OPMD acts as a catastrophic ecological event. The structural breakdown of the keratinised mucosa, combined with localised hypoxia and altered salivary flow, disrupts this symbiotic balance. Microbiomic profiling of dysplastic biopsy samples reveals a stark, progressive decline in overall microbial alpha diversity (the sheer number of unique species within the lesion)⁶. This loss of diversity creates an ecological vacuum that is rapidly colonised by highly virulent, anaerobic, and pro-inflammatory consortia. Consequently, the microbiota shifts from a state of protective commensalism to a state of active, pathogenic dysbiosis, which serves as the biological bedrock for cellular dysplasia⁷.

Microbiological Signatures of Specific Pre-Neoplastic Lesions

Distinct OPMDs present with unique, highly specific microbiological signatures, suggesting that different pre-neoplastic clinical presentations may be driven by distinct bacterial profiles. For instance, in conventional homogeneous leucoplakia, researchers consistently observe a marked enrichment of *Porphyromonasasteri* and specific *Campylobacter* species, alongside a significant depletion of protective *Rothia* species⁸.

Proliferative verrucous leukoplakia (PVL), which carries a daunting malignant transformation rate exceeding 70%, exhibits an even more aggressive microbial shift. PVL lesions show a severe, deep-tissue infiltration of *Prevotella salivae* and *Campylobacter jejuni*. Furthermore, the fungal-bacterial axis plays a critical role in these aggressive phenotypes. The hyphal infiltration of *Candida albicans* is frequently observed in non-homogeneous leukoplakias. *C. albicans* acts synergistically with local bacteria by producing carcinogenic nitrosamines and acetaldehyde from dietary ethanol, directly inducing DNA double-strand breaks in the basal epithelial layer⁹.

As the OPMD degrades into an invasive OSCC, the local microbiome is rapidly and decisively overrun by the phylum *Fusobacteriota*. In late-stage carcinomas, *Fusobacterium* species can constitute over 30% of the entire lesional microbiome, a stark contrast to the <2% relative abundance observed in healthy mucosal tissues¹⁰.

Molecular Mechanisms of Microbially Driven Carcinogenesis

The malignant transformation of an OPMD is not a passive consequence of bacterial colonisation; rather, it is actively engineered by the microbiome through three primary molecular mechanisms: chronic inflammatory hyperactivation, the induction of cellular invasion, and profound immune subversion.

Chronic Inflammatory Hyperactivation and Oxidative Stress

Pathogenic dysbiosis triggers a sustained, low-grade inflammatory cascade that is highly toxic to the host genome. Polymicrobial biofilms within dysplastic lesions continuously activate the host's innate immune system via Toll-like receptors (TLRs), specifically TLR2 and TLR4¹¹. This chronic receptor engagement hyperactivates the nuclear factor kappa B (NF-κB) and IL-6/STAT3 signalling pathways within the epithelial cells. The resulting continuous secretion of tumour necrosis factor-alpha (TNF-α), interleukin-1 beta (IL-1β), and interleukin-6 (IL-6) attracts a vast influx of neutrophils and macrophages to the lesional site¹². These inflammatory cells release copious amounts of reactive oxygen species (ROS) and reactive nitrogen species (RNS). This intense oxidative stress overwhelms the epithelial cell's antioxidant defences, causing direct mutagenic damage to host DNA and accelerating the progression from low-grade to high-grade dysplasia¹³.

Induction of the Epithelial-Mesenchymal Transition (EMT)

The epithelial-mesenchymal transition (EMT) is the critical biological threshold where dysplastic epithelial cells lose their rigid cellular polarity and intercellular adhesion, acquiring the migratory and invasive properties that define a true malignancy. Keystone periopathogens directly orchestrate this transition. Specific bacterial adhesins forcefully disrupt the structural integrity of the epithelium by cleaving E-cadherin—the primary transmembrane protein responsible for anchoring epithelial cells together¹⁴. The destruction of E-cadherin releases intracellular β-catenin, which translocates into the nucleus and forcibly upregulates the transcription of powerful EMT-inducing transcription factors, such as ZEB1, Twist, and Snail¹⁵.

Immune Evasion and Apoptosis Inhibition

To ensure their own survival within the harsh tumour microenvironment, dysbiotic pathogens actively suppress the host's adaptive immune response. Intracellular bacteria secrete specific effector proteins that upregulate the expression of Programmed Death-Ligand 1 (PD-L1) on the surface of dysplastic oral cells. This PD-L1 overexpression effectively blinds circulating cytotoxic T-lymphocytes (CD8+ T cells), granting the pre-malignant cells an immunological "free pass" to proliferate without restraint¹⁶.

Synergistic Pathogenicity: The Role of Keystone Pathogens

While the entire dysbiotic community contributes to oncogenesis, the periopathogenic bacteria *Fusobacterium nucleatum* (*F. nucleatum*) and *Porphyromonas gingivalis* (*P. gingivalis*) have been unequivocally identified as the primary aetiological accelerators of tumour progression.

F. nucleatum, a Gram-negative anaerobe, functions as a master bridging coloniser. It secretes a highly virulent adhesion protein known as FadA, which is the exact mechanism responsible for the aforementioned E-cadherin cleavage and β -catenin activation. By physically breaking down the intercellular junctions, *F. nucleatum* essentially unlocks the epithelial barrier, allowing other, less invasive pathogens to penetrate deep into the connective tissue stroma¹⁷.

Simultaneously, *P. gingivalis* aggressively invades the host epithelial cells, thriving as an intracellular pathogen. Once inside, it exerts profound anti-apoptotic effects, effectively immortalising the dysplastic cells by upregulating anti-apoptotic proteins like Bcl-2 while simultaneously suppressing pro-apoptotic pathways (e.g., Bax and

caspase-3). Furthermore, *P. gingivalis* secretes an array of highly destructive hydrolytic enzymes, known as gingipains, which degrade the extracellular matrix and activate host matrix metalloproteinases (specifically MMP-9). This enzymatic degradation systematically dissolves the basement membrane, physically paving the way for the tumour cells to invade the underlying submucosa and access the vascular network¹⁸.

Data Profile: Quantitative Microbial Shifts and Inflammatory Metrics

The following statistical data profile synthesises aggregate multi-omics sequencing metrics and corresponding inflammatory marker expressions, mapping the precise biological shifts that occur during the malignant transformation from healthy mucosa to invasive OSCC.

Clinical Histological State	Alpha Diversity Score (Chao1 Index)	Dominant Healthy Phyla (Firmicutes)	Protumorigenic Enrichment (Fusobacteriota)	Peak Tissue Inflammatory Metric (IL-6 expression)
Healthy Mucosa	Very High (>450)	~ 68.2%	< 2.1%	Baseline (1.0x)
Homogeneous Leucoplakia	Moderate (320 - 410)	~ 51.4%	~ 8.4%	Elevated (3.4x)
Proliferative Verrucous Leukoplakia (PVL)	Low (210 - 310)	~ 38.6%	~ 18.7%	Highly Elevated (7.2x)
Invasive OSCC	Very Low (<200)	< 25.0%	> 30.5%	Severe/Hyperactive (14.5x)

CONCLUSION

The unravelling of the oral microbiome marks a critical evolutionary milestone for the discipline of oral pathology. We can no longer view the malignant transformation of OPMDs as an isolated event dictated solely by host genetics. The local microbiota is a highly active, protumorigenic driver that orchestrates chronic inflammation, directly induces the epithelial-mesenchymal transition, and severely compromises host immune surveillance. Recognising microbial dysbiosis as a primary aetiological accelerator opens profound new avenues for clinical management. By profiling the precise microbial landscape of dysplastic lesions via high-throughput sequencing, clinicians are gaining the ability to accurately predict the likelihood of malignant transformation. Ultimately, this molecular understanding lays the groundwork for highly targeted microecological interventions—ranging from precision antimicrobials to genetically modified probiotics—designed to restore mucosal haemostasis and halt the progression of oral cancer before it ever breaches the basement membrane.

REFERENCES

- Warnakulasuriya S. Global epidemiology of oral potentially malignant disorders. *Oral Diseases*. 2020;26(1):30-37.
- Speight PM, Epstein J, Kujan O, et al. Screening and early detection of oral cancer and potentially malignant disorders. *Expert Review of Anticancer Therapy*. 2021;21(9):949-960.
- Herreros-Pomares A, Hervás D, Bagan-Debón L, et al. On the Oral Microbiome of Oral Potentially Malignant and Malignant Disorders: Dysbiosis, Loss of Diversity, and Pathogens Enrichment. *International Journal of Molecular Sciences*. 2023;24(4):3466.
- Špiljak B, Ozretić P, Andabak Rogulj A, et al. Oral Microbiome Research in Biopsy Samples of Oral Potentially Malignant Disorders and Oral Squamous Cell Carcinoma and Its Challenges. *Applied Sciences*. 2024;14(23):11405.
- Sarkar A, Sengupta S, et al. Alteration of the oral microbiome in oral leukoplakia: A systematic review. *Journal of Oral Pathology & Medicine*. 2021;50(7):643-650.
- Intini R, et al. Comparative analysis of oral microbiome in saliva samples of oral

- leukoplakia, proliferative leukoplakia and oral squamous cell carcinoma. *Scientific Reports*. 2022;12(1):14521.
7. Al-Hebshi NN, Nasher AT, Maryoud MY, et al. Inflammatory bacteriome featuring *Fusobacterium nucleatum* and *Pseudomonas aeruginosa* identified in association with oral squamous cell carcinoma. *Scientific Reports*. 2017;7(1):1834.
 8. Geng F, Wei Y, et al. *Candida albicans* promotes oral squamous cell carcinoma progression through the induction of inflammatory cytokines and oxidative stress. *Infection and Immunity*. 2022;90(5):e0011422.
 9. Binder Gallimidi A, Fischman S, Revach B, et al. Periodontal pathogens *Porphyromonas gingivalis* and *Fusobacterium nucleatum* promote tumor progression in an oral-specific chemical carcinogenesis model. *Oncotarget*. 2015;6(26):22613–22623.
 10. Sukmana BI, Saleh RO, Najim MA, et al. Oral microbiota and oral squamous cell carcinoma: a review of their relation and carcinogenic mechanisms. *Frontiers in Oncology*. 2024;14:1319777.
 11. Pignatelli P, Nuccio F, Piattelli A, Curia MC. The Role of *Fusobacterium nucleatum* in Oral and Colorectal Carcinogenesis. *Microorganisms*. 2023;11(9):2358.
 12. Kamarajan P, Hayami T, et al. *Porphyromonas gingivalis* promotes tumor progression and evasion of host immunity in oral squamous cell carcinoma. *Journal of Dental Research*. 2020;99(9):1070-1078.
 13. Katz J, Onate MD, Pauley KM, et al. Presence of *Porphyromonas gingivalis* in gingival squamous cell carcinoma and its role in anti-apoptosis. *International Journal of Oral Science*. 2011;3(4):209-215.
 14. Rubinstein MR, Wang X, Liu W, et al. *Fusobacterium nucleatum* promotes colorectal carcinogenesis by modulating E-cadherin/beta-catenin signaling. *Cell Host & Microbe*. 2013;14(2):195-206.
 15. Zhang L, Liu Y, Zheng HJ, et al. The oral microbiota may have influence on oral cancer progression through Wnt/beta-catenin signaling pathways. *Frontiers in Cellular and Infection Microbiology*. 2020;9:476.
 16. Lee WH, Chen HM, Yang SF, et al. Bacterial alterations in salivary microbiota and their association in oral cancer patients treated with immune checkpoint inhibitors. *Cancers*. 2021;13(15):3729.
 17. Yang CY, Yeh YM, Yu HY, et al. Oral microbiota dysbiosis and its association with oral cancer invasion and metastasis. *Journal of Clinical Medicine*. 2018;7(4):81.
 18. Song X, Wang J, Gu Z, et al. *Porphyromonas gingivalis* and *Fusobacterium nucleatum* synergistically strengthen the effect of promoting oral squamous cell carcinoma progression. *Infectious Agents and Cancer*. 2025;20(1):14.

How to cite this article: Dr. Jayesh Kanjariya, Dr. Jinal Koladiya, Dr. Ruchi Patel, Dr. Jigar Thakkar, Dr. Kruti Patel, Dr. Kavita Prajapati, Dr. Keval Patel. THE MICROECOLOGICAL AETIOLOGY OF ORAL CANCER: DECIPHERING THE ROLE OF THE ORAL MICROBIOME IN THE MALIGNANT TRANSFORMATION OF OPMDS, Asian J. Med. Res. Health Sci., 2026; 4 (2):730-733.

Source of Support: Nil, Conflicts of Interest: None declared.